Auspex Pharmaceuticals (La Jolla, CA), a clinical-stage pharmaceutical company focused on hyperkinetic movement disorders including Huntington’s disease, Tourette syndrome and tardive dyskinesia, closed a $25M Series D financing. Participants include Panorama Capital, Thomas, McNerney & Partners, CMEA Capital and Sloan Biotech Fund. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and […]
Prosensa Therapeutics (Netherlands) a clinical-stage biopharmaceutical company focused on RNA-modulating therapeutics for Duchenne’s Muscular Dystrophy, Huntington’s disease and myotonic dystrophy, closed a $30.7M Series A financing. Participants include New Enterprise Associates, Abingworth Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital.